1 |
Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, Bruno MJ, Peppelenbosch MP, Haagmans BL, Pan Q. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. [DOI: 10.1038/s41422-022-00618-w] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 34.0] [Reference Citation Analysis]
|
2 |
Hsu J, Hsu P, Shie C, Chuah S, Wu I, Huang W, Tang S, Tsai K, Kuo L, Ghose S, Hsu J, Shih C. Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users. Medicina 2022;58:436. [DOI: 10.3390/medicina58030436] [Reference Citation Analysis]
|
3 |
Groaz E, De Clercq E, Herdewijn P. Anno 2021: Which antivirals for the coming decade? Annu Rep Med Chem 2021;57:49-107. [PMID: 34744210 DOI: 10.1016/bs.armc.2021.09.004] [Reference Citation Analysis]
|
4 |
Murayama A, Momose H, Yamada N, Matsubayashi K, Muramatsu M, Hamaguchi I, Kato T. Performance Evaluation of In Vitro Screening and Diagnostic Kits for Hepatitis C Virus Infection. Front Cell Infect Microbiol 2022;11:793472. [DOI: 10.3389/fcimb.2021.793472] [Reference Citation Analysis]
|
5 |
Chen M, Xu Y, Li N, Yin P, Zhou Q, Feng S, Wu T, Wei L, Wang H, Fu Y, Li Y. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus. Journal of General Virology 2021;102. [DOI: 10.1099/jgv.0.001704] [Reference Citation Analysis]
|